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INTRODUCTION
Ionizing radiation was used to treat children for skin hemangioma until the end of the fifties in most Western countries [6, 12] . The great majority of children were treated with 226 Ra tubes, sheets and needles, and a minority received x-ray contact-therapy. The long-term carcinogenic consequences of such treatments are still being studied intensively in Sweden [6, 7, 8, 11, 14, 15, 16] , and cohort studies performed for this purpose are now considered one of the major sources of information about the carcinogenic effects of ionizing radiation in infancy.
In France, during the 1940-1973 period, 7826 children below 15 years of age (6 months on average) were treated for skin hemangioma at the Institut Gustave-Roussy. Radiotherapy was delivered using beta, gamma and/or x-rays in 70% of cases. Several studies [3, 5] have investigated the late effects of the different techniques used to treat skin hemangioma but none of them focused on the possible long-term effects of beta applicators. In addition, the previous studies exclusively concerned specific skin and thyroid effects.
In the context of the European Radiation Protection Program (Contract N° F14P-CT95-0009), we decided with Swedish colleagues to constitute the cohort described in this study.
The main objective was to describe the hemangioma cohorts in the Karolinska Hospital (Stockholm), Sahlgrenska University Hospital (Gothenberg), and the Institut Gustave-Roussy (Villejuif), placing special emphasis on treatments and dose calculations. The three pooled cohorts were then used to investigate the carcinogenic effect of radiation therapy during early childhood. Individual analyses are also ongoing for each cohort. This paper presents the mortality analysis conducted on the French cohort.
METHODS AND MATERIAL
Patients
Information about patients and treatments was extracted from the medical records of the Institut Gustave-Roussy. A total of 8303 patients were verified. Among these patients, 503
were excluded due to the following reasons : 385 had been treated after 15 years of age, 26 had died before 1969, when individual causes of death began to be registered in France, 92
had been treated before 1940, a period during which the exhaustiveness of the IGR medical records cannot be guaranteed.
For the remaining 7800 patients, the vital status of the 7037 included in our analysis was obtained from the National Institute of Statistics and Economic Studies (INSEE). We were unable to obtain the vital status for the other 763 patients who were therefore excluded HAL author manuscript inserm-00117150, version 1 from the analysis. for such treatments in the 1950s and gradually replaced the radium sources in order to eliminate the potential effects of their gamma rays. A detailed description of the radioactive applicators has already been published [21] . X-ray treatments were mainly given with contact-therapy using a 50 kV peak with a 1 mm Al filter, and a short focus distance. The radiotherapy technique chosen depended on the surface and on the thickness of the hemangioma [19] .
The preliminary studies [3, 5] on radiation-induced effects on the skin and thyroid following treatment for skin hemangioma in childhood, were based on simplified dose calculation models. These models were specific to the sites studied but could not be adjusted for the estimation of doses delivered to other sites in the body in accordance with the European cohort study requirements. The ICTA software was developed for this purpose.
ICTA stands for Individualized phantom based on CT slices of a real human body, using
Auxological data. Individuals of various ages and the different applicators used to treat skin HAL author manuscript inserm-00117150, version 1
hemangiomas can be simulated with this software and all radium and beta applicator characteristics are included. These applicators are placed on the patient according to the information found in the patient's file (drawing, description, photographs). Doses delivered to 151 anatomical landmarks distributed throughout the body can be estimated with the ICTA dose calculation algorithm. The general structure of the ICTA software has previously been described [20] , and the simulation of individuals has been detailed elsewhere [13] . Similar calculations were performed for x-ray treatments using Dos_EG [4] and the detailed dose data were recorded in the dose database. For patients with more than one radiotherapy session, the doses calculated at the same site for the different sessions were summed up and recorded as the estimated dose delivered to that site for a given patient and were used to correlate doses to possible effects, if any.
The mean doses to the brain (7 points of estimation), eye (1 point of estimation by eye), breast (1 point of estimation by breast), thyroid (2 points of estimation), colon (5 points of estimation), and lung (5 points of estimation by lung) were, respectively, 80 mGy, 140 mGy, 80 mGy, 40 mGy, <10 mGy and 30 mGy ( Table 2 ). The weighted average active bone marrow dose was calculated from the doses estimated for the 91 points of the skeleton, using age-dependent coefficients for 20 parts of the body published by Cristy [2] . The effective dose was calculated using coefficients published in ICRP Report 73 [10] . The effective dose is defined in ICRP Report 60 as a summation of the equivalent doses for organs, with the term for each organ multiplied by an appropriate tissue weighting factor [9] .
Statistical analysis
The period at risk for each subject began from the initiation of hemangioma treatment or January 1 st 1969, if treated before this date, and ended at the time of death or January 1 st 1998. Before 1969, 18978 persons-years of follow-up were lost, 69% of which concerned female patients, 83% in patients under 1 year of age when treated and 67% in patients who had received radiotherapy.
Reference mortality rates, according to sex, calendar year, age, and cause of death, in the general French population were obtained from the CépiDc INSERM, as well as the abovementioned causes of death in our series, in order to estimate the standardized mortality ratio (SMR). These national mortality rates were used because the patients now live all over
France.
Both external and internal analyses were performed. The SMR variations according to radiotherapy or not, sex, age at first treatment, date of treatment, year of follow-up, attained age and calendar year were studied assuming Poisson distribution of the expected number of deaths [1] . The 95% CI confidence intervals were calculated using maximum likelihood methods [17] . Calculations were made using AMFIT® software [18] . SMR and relative risk (RR) variations according to radiotherapy or not, the type of treatment and the effective dose were then studied.
RESULTS
Between 1969 to 1997, 123 patients died in the cohort, of whom 85 had received radiotherapy (Table 3) . No excess of total deaths was observed for patients who had received radiotherapy compared to the general population (SMR = 0.99 ; 95% CI = 0.79-1.22). The same result was observed for patients who had not received radiotherapy compared to the general population (SMR = 0.96 ; 95% CI = 0.69-1.30).
During this period, 18 patients in the cohort, 15 of whom had received radiotherapy, had there initial, immediate and associated causes of death recorded as "symptoms, signs and ill-defined conditions". For this category, compared to the general population, there was a significant excess of mortality among irradiated patients (SMR = 2.2 ; 95% CI = 1.2-3.4) ( Table 3) .
During this period, 16 patients in the cohort died of cancer, 14 of whom had received radiotherapy (Table 3) . A non significant excess of cancer-related mortality was observed for patients who had received radiotherapy as compared to the general population (SMR = Compared to the general population, the analysis of the other major causes of death among irradiated patients, as defined by the World Health Organization, evidenced a significant deficit of mortality due to external causes (SMR = 0.67 ; 95% CI = 0.46-0.94) and a significant excess of mortality due to symptoms, signs and ill-defined conditions (SMR = 2.2 ; 95% CI = 1.2-3.4) ( .07). The other types of irradiation (beta and x-rays) had no effect.
The average effective dose among patients who had received radiotherapy was 22 mSv and the median value was 0.1mSv. Eight patients received an effective dose that was higher than 1 Sv. Of these 8 patients, 4 were treated with X-rays alone, 2 with X-rays, 226 Ra, and 32 P, 1 with X-rays and 90 Sr, and 1 with 226 Ra alone.
After stratifying on other variables, no evidence was found for a relation between the effective dose of radiation and the risk of cancer-related mortality (χ 2 = 115.13 -114.99 = 0.14). Table 4 describes the doses received at the cancer site for the 14 cancer deaths, as well as the effective and maximum dose for these patients.
DISCUSSION
Based on the 85 deaths in the radiotherapy group, 14 of which occurred during the 31 years of follow-up and were due to cancer, we evidenced a non significant excess of mortality following treatment with 226 Ra, but not for patients who had received x-rays, 32 P, 90 Sr, 90 Yr.
We were unable to establish a dose-response relation between the effective dose and all causes and cancer mortality.
Potential biases may limit the interpretation of our results. A total of 763 (10%) patients
were excluded from this study because we were unable to obtain their vital status. The identification data in the IGR medical records concerning these patients did not match those obtained from the INSEE. As the quality of the identification data in the medical records was likely linked to the number of consultations at the IGR, during which information could have been updated, patients with poor quality identification data probably underwent fewer consultations than the others. However, as included and excluded patients were comparable, this bias is probably low (Table 1) .
There is an apparent contradiction between the significant excess of cancer mortality in patients who had received radiotherapy, in particular with 226 Ra sources, and the absence of a dose-response relation for the effective dose values. In addition, the effective dose, the maximal dose and the dose estimated at the cancer site were all lower than the corresponding mean values in the radiotherapy group. This discrepancy could be due to several reasons.
Firstly, the observed excess mortality, only significant for radiotherapy and well nigh significant for 226 Ra, could be due to chance. Secondly, the effective dose is not a good indicator of the radiation dose, if irradiation is heterogeneous. This plausible explanation is nevertheless partly counterbalanced by our results for the maximal dose at any site, and the dose at the cancer site. Other reasons may be due to uncertainties in dose estimation due to unavailable data, e.g. unknown position of patients during treatments. One of the dosimetric parameters is the source-target distance which was calculated assuming patients were lying down during the treatment session. If the patient had been sitting, this would have led to an overestimation of the source-site distance.
The doses estimated to the main organs of the body delivered by 226 Ra sources were higher than those delivered by 32 P, 90 Sr, 90 Yr but lower than those delivered by x-rays.
Caution should be exercised when interpreting the excess of cancer-related mortality among patients who had received 226 Ra, as compared to the others. Indeed, these patients had a longer follow-up, and were, on average, 35 years old at the end of the follow-up, compared to 31 years (0-59) on average for the others. Notwithstanding, we did not evidence an increased SMR with attained age ; the shorter follow-up in other patients reduces the capacity to evidence an excess and thus could account for this difference.
It is not possible for us to estimate the relation between the organ dose and the later risk of cancer-related death due to the small number of cancer-related deaths in our cohort (a total of 14) and to the variability of the organs in which these fatal cancers developed, [1 death for each type of organ, except for the brain (3 deaths) and pancreas (2 deaths)].
Except for the brain, the average organ dose we estimated for patients treated with 226 Ra was at least 2-fold lower than that estimated in the Stockholm and Gotenburg cohort studies ( [7] . We did not find excess mortality due to external causes (trauma) ( Table 4 ), unlike that observed in the Swedish cohort [7] . We have no explanation for the excess of deaths from "symptoms, signs and ill-defined conditions" which is not linked to the quality of the data since the national database of causes of death was used both to compute the reference rates and to identify the causes of death in our cohort.
At the end of the follow-up, the patients in our cohort were still young, 31 years on average (0-59). Only 9.1 cancer-related deaths were expected in our cohort, as compared to 91 in the Stockholm cohort. In addition to the young age of patients at the end of the followup, we studied cancer mortality rather than cancer incidence, thus reducing the power to detect an excess for all cancer sites together. For tumors with a good prognosis (e.g. breast and thyroid [3] ), which were more likely to have been irradiated in our cohort, the power to detect excess mortality is very low in our study.
Our analysis was able to detect a SMR of 2 or higher with a reasonable power (80%).
Such a SMR was unexpected in our cohort, due to the average effective dose of 20 mSv. On the other hand, during the following 20 years (1997-2017), a total of 70 cancer-related deaths are expected in our cohort after radiotherapy, in the absence of an increased risk of cancerrelated mortality. It will then be possible to detect a SMR of 1.3. Such an increase of 30% is what was observed in the Stockholm cohort [7] , with the doses received by most organs attaining about 4-fold higher than that observed in our cohort.
In conclusion, this study suggests an excess risk of cancer-related mortality in patients treated during early childhood with radiotherapy for skin hemangioma, especially with 226 Ra.
Moreover, the Swedish experience shows that these patients should be followed-up because they are at an increased risk of developing a cancer in the future. 1962 (1941-1973) 1966 (1944-1973) 1966 (1949-1973) 1968 (1950-1973) 1967 (1941-1973) 1967 (1941-1973) Follow-up (years) 35 ( * The vital status of patients has been assessed, but matching with the national database of causes of death was not possible, probably because of errors in identification. 2 maximum dose to any site for the cohort (mean ; median) : (1300 mGy; 82 mGy) 3 doses to the following sites for the cohort (mean ; median) : pancreas (12 mGy ; <0.01 mGy), lung (30 mGy ; <0.01 mGy), ovaries (4 mGy ; <0.01 mGy), testis (20 mGy ; <0.01 mGy), brain (79 mGy ; <0.01 mGy) and bone marrow (37 mGy ; 0.4 mGy) 
